ArticleNature communications2025

High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models.

Juan Carlos Álvarez-Pérez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.